While progress has been made in fighting diseases disproportionally affecting underserved populations, unmet medical needs persist for many neglected tropical diseases. The World Health Organization has encouraged strong public-private partnerships to address this issue and several public and private organizations have set an example in the past showing a strong commitment to combat these diseases. Pharmaceutical companies are contributing in different ways to address the imbalance in research efforts. With this review, we exemplify the role of a public-private partnership in research and development by the journey of our dengue antiviral molecule that is now in early clinical development. We detail the different steps of drug development and outline the contribution of each partner to this process. Years of intensive collaboration resulted in the identification of two antiviral compounds, JNJ-A07 and JNJ-1802, the latter of which has advanced to clinical development.
【저자키워드】 COVID-19, Coronavirus disease 2019, DENV, dengue virus, public-private partnership, WHO, World Health Organization, TB, Tuberculosis, SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2, FDA, Food and Drug Administration, GPH, global public health, GLP, good laboratory practice, BARDA, Biomedical Advanced Research and Development Authority, NHP, non-human primates, ACTIV, an accelerating COVID-19 therapeutic interventions and vaccines, ADME, absorption distribution metabolism and excretion, CD3, Center for Drug Design and Discovery, Dengue antiviral research and development, DVI, dengue vaccine initiative, EIF, European Investment Fund, IMI, Innovative Medicines Initiative, MMV, Medicines for Malaria Venture, MPD, Mectizan® Donation Program, NME, new molecular entity, NS, non-structural protein, NTD, neglected tropical disease, PPP, public-private partnership, SAR, structure-activity-relationship, UNITE4TB, academia and industry united innovation and treatment for tuberculosis,